Targeting the NKG2D axis in head and neck squamous cell carcinoma: from molecular insights to clinical applications
Parsa Alijanizadeh, Mahshid Shahmoradi, Amirhossein Kamroo, Tara Shahmoradi, Fatemeh Tajafrooz, Pegah khodaee, Niloufar Yazdanpanah, Kiarash Saleki, Nima Rezaei · 2026
Read Targeting the NKG2D axis in head and neck squamous cell carcinoma: from molecular insights to clinical applications by Parsa Alijanizadeh, Mahshid Shahmoradi, Amirhossein Kamroo, Tara Shahmoradi, Fatemeh Tajafrooz, Pegah khodaee, Niloufar Yazdanpanah, Kiarash Saleki, Nima Rezaei (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13383504.txt.
Description
Parsa Alijanizadeh's team reviews strategies to restore the NKG2D immune axis in head and neck cancer, in a 2026 review. Head and neck squamous cell carcinoma evades immune surveillance by crippling NKG2D on natural killer cells and killer T cells, shedding stress ligands and secreting suppressive cytokines such as TGF-beta1. The review surveys ways to rearm this axis.
Cytokines such as IL-2 and IL-15 boost NKG2D-driven natural killer activation, while antibodies against MICA, MICB, and ULBP ligands block shedding and trigger cell killing. Engineered NKG2D CAR-T and CAR-NK cells show potent preclinical activity, and pairing with EGFR antibodies or checkpoint blockers adds benefit. Tumor heterogeneity and suppressive signals remain hurdles to clinical translation.
Catalog record
| CREATOR | Parsa Alijanizadeh, Mahshid Shahmoradi, Amirhossein Kamroo, Tara Shahmoradi, Fatemeh Tajafrooz, Pegah khodaee, Niloufar Yazdanpanah, Kiarash Saleki, Nima Rezaei |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 49 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |